Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials.
- Authors
- David, Sean P; Johnstone, Elaine C; Churchman, Michael; Aveyard, Paul; Murphy, Michael F G; Munafò, Marcus R
- Year
- 2011
- Journal
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
- PMID
- 21330274
- DOI
- 10.1093/ntr/ntq246
- PMCID
- PMC3107615
INTRODUCTION: Cigarette smoking remains the leading cause of preventable death worldwide. However, the efficacy of available first-line therapies remains low, particularly in primary care practice where most smokers seek and receive treatment. These observations reinforce the notion that 'one size fits all' smoking cessation therapies may not be optimal. Therefore, a translational research effort was launched by the Imperial Cancer Research Fund (later Cancer Research UK) General Practice Research Group, who led a decade-long research enterprise that examined the influence of pharmacological hypothesis-driven research into genetic influences on drug response for smoking cessation with transdermal nicotine replacement therapy in general practice. METHODS: New and previously published smoking cessation genetic association results of 30 candidate gene polymorphisms genotyped for participants in two transdermal nicotine replacement clinical trials based in UK general practices, which employed an intention to analyze approach. RESULTS: By this high bar, one of the polymorphisms (COMT rs4680) was robust to correction for multiple comparisons. Moreover, future research directions are outlined; and lessons learned as well as best-practice models for designing, analyzing, and translating results into clinical practice are proposed. CONCLUSIONS: The results and lessons learned from this general practice-based pharmacogenetic research programme provide transportable insights at the transition to the second generation of pharmacogenetic and genomic investigations of smoking cessation and its translation to primary care.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Single Nucleotide Polymorphisms Within <i>DRD2, COMT, and DBH</i> and Smoking Cessation: A Systematic Review Considering Genetic Differences by Ancestry and Biological Sex. | Jones SK et al. | — | 2024 | → |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | — | 2023 | → |
| Catechol-O-Methyltransferase Effects on Smoking: A Review and Proof of Concept of Sex-Sensitive Effects. | DeVito EE et al. | — | 2022 | → |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | — | 2018 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | — | 2016 | → |
| What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses. | Le Foll B | — | 2016 | → |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | — | 2015 | → |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | — | 2015 | → |
| An Association between Emotional Responsiveness and Smoking Behavior. | Keeley RD et al. | — | 2013 | → |
| APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset. | Kalapatapu RK et al. | — | 2013 | → |
| A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback. | Lee MR et al. | — | 2013 | → |
| Biomarkers for smoking cessation. | Bough KJ et al. | — | 2013 | → |
| Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatment. | Shields AE et al. | — | 2013 | → |
| Cardiovascular responses induced by Catalase Inhibitior into the Fourth Cerebral Ventricle is changed in Wistar rats exposed to sidestream cigarette smoke. | Valenti VE et al. | — | 2013 | → |
| Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. | McClure JB et al. | — | 2013 | → |
| Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. | Spruell T et al. | — | 2012 | → |
| Nicotine patches--do they influence seizure number, stay durations or seizure rate during video EEG telemetry? | Parikh MS et al. | — | 2012 | → |
| Testing times. | Ware J et al. | — | 2012 | → |
| Biomarkers to optimize the treatment of nicotine dependence. | Schnoll RA et al. | — | 2011 | → |